Test Price
1,200 AED✅ Home Collection Available
HLA Panel Reactive IgG Antibodies (PRA) Screen in UAE | 1200 AED | Pre-Transplant Immunological Assessment
Executive Summary & Core Metrics
Executive Summary: The HLA Panel Reactive IgG Antibody (PRA) Screen provides precise quantification of pre-formed anti-HLA antibodies, offering 99.9% diagnostic sensitivity to stratify transplant rejection risk. Performed at our ISO-accredited (ISO 9001:2015, Cert: INT/EGQ/2509DA/3139) laboratory in Dubai Healthcare City, this test enables precise donor-recipient immunological matching using advanced Luminex X-MAP technology.
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO Accredited Processing (ISO 9001:2015, Cert: INT/EGQ/2509DA/3139).
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM).
- Clinical Guidance: Telephonic Post-Test Clinical Guidance for result interpretation by our specialist medical team.
- Insurance: Direct Billing Verification via WhatsApp at +971 54 548 8731.
Test Overview & Methodology
The HLA Panel Reactive IgG Antibody (PRA) Screen quantifies the percentage of pre-formed IgG antibodies against a panel of human leukocyte antigens, providing a critical risk stratification tool for solid organ and hematopoietic stem cell transplantation. Our ISO-certified Luminex X-MAP bead-based assay delivers superior sensitivity and specificity compared to conventional complement-dependent cytotoxicity methods, enabling precise donor-recipient immunological matching.
| Feature | Our HLA PRA IgG Screen (Luminex X-MAP) | Standard Complement-Dependent Cytotoxicity (CDC) |
|---|---|---|
| Methodology | Luminex X-MAP bead-based multiplex flow cytometry | Complement-dependent cytotoxicity assay |
| Antibody Detection | All IgG HLA antibodies, including non-complement-fixing | Only complement-fixing antibodies (misses non-complement-activating) |
| Sensitivity | >99% for clinically relevant HLA antibodies | ~80% (low sensitivity for non-cytotoxic antibodies) |
| Specificity | High specificity with single antigen bead discrimination | Lower specificity, can show cross-reactive results |
| Turnaround Time | 10–12 Business Days | 5–7 Business Days (less informative) |
| Clinical Interpretation | Quantitative %PRA and antibody specificity for precise donor allocation | Qualitative positive/negative; often requires follow-up testing |
Physician Insight & Safety Protocols
"As a General Practitioner involved in pre-transplant workup, I recognize the emotional journey patients and their families undergo while awaiting transplantation. This PRA screen delivers critical immunological insight, yet it must be interpreted as part of a comprehensive clinical picture. A positive result identifies sensitization and provides the transplant team with a roadmap toward compatible donors or individualized desensitization protocols. Always maintain open dialogue with your multidisciplinary transplant committee and never alter prescribed immunosuppressant regimens without direct specialist consultation."
— Dr. Ajay Singh (DHA License: 36234132), General Practitioner
Critical Medication Advisory
Do not discontinue any prescribed immunosuppressive or anti-rejection medications without explicit consultation with your transplant specialist. Abrupt medication cessation can lead to acute graft rejection and life-threatening complications.
Exclusion Criteria & Emergency Red Flags
- Testing is not suitable if you have received intravenous immunoglobulin (IVIG) or rituximab within the last 3 months, as these agents may interfere with accurate HLA antibody detection.
- Avoid blood collection during active systemic infection or if an untreated bleeding disorder is present; consult your referring physician before proceeding.
- Seek immediate emergency medical care (Emergency Room) if you experience any of the following signs suggestive of acute transplant rejection:
- Sudden-onset pain, focal tenderness, or visible swelling directly over the transplant site
- Fever exceeding 38°C without an identifiable infectious source
- Unexplained and marked decrease in urine output (kidney transplant) or new-onset jaundice (liver transplant)
- Progressive dyspnea, new cough, or oxygen desaturation (lung or heart transplant)
Patient FAQ & Clinical Guidance
1. What does a positive PRA screen mean for my transplant eligibility?
A: A positive PRA screen indicates the presence of circulating IgG antibodies directed against human leukocyte antigens. This finding suggests immunological sensitization, which may make it more challenging to find a fully compatible donor or increase the risk of antibody-mediated rejection. Your transplant team will use the specific antibody profile and calculated PRA percentage to evaluate donor compatibility, consider desensitization therapies, or guide organ allocation strategies. Our telephonic clinical guidance service is available to help you understand your personalized risk profile.
2. How should I prepare for the PRA blood test?
A: No special dietary restrictions are required. For optimal accuracy, blood collection should ideally be performed 48 hours after a dialysis session if you are on hemodialysis. Please inform our phlebotomist about any recent blood transfusions, IVIG therapy, or rituximab administration, as these can interfere with test results. Our mobile phlebotomy team will verify eligibility at the time of collection to ensure the sample is drawn under optimal conditions.
3. How quickly will I receive my PRA results and what do they show?
A: Your Luminex PRA report is typically delivered within 10 to 12 business days from sample collection. The report provides a quantitative panel reactive antibody percentage (PRA%), a detailed list of identified donor-specific anti-HLA antibody specificities, and an interpretation of your immunological risk profile. This comprehensive data allows your transplant team to perform precise risk stratification. You will receive a notification via WhatsApp once the report is available, and we offer a post-test telephonic discussion with a clinical specialist to clarify any questions.
UAE Regulatory & Data Privacy Adherence
Your Data Privacy and Safety Are Our Commitment
All personal data and clinical information are processed in strict compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL). The handling of health data and electronic medical records adheres fully to Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Patient safety protocols and clinical consent procedures are governed by Federal Decree-Law No. 4 of 2016 on Medical Liability, ensuring the highest standard of care and transparency throughout the diagnostic process.
Clinical & Logistical Metadata
| Test Name | HLA Panel Reactive IgG Antibodies (PRA) Screen |
| Price (AED) | 1,200 |
| Turnaround Time | 10–12 Business Days |
| Sample Type / Matrix | Serum (Standard Peripheral Whole Blood) |
| Methodology Used | Luminex X-MAP Multiplex Bead-Based Flow Cytometry |
| ICD-10-CM Code | Z01.818 |
| LOINC Code | 34637-6 |
| DHA Facility License & Laboratory Address | DHA License: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | Corporate Lab: DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians